Drug Trial Radar · NCT01316874
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Nov 1993
Primary completion
Apr 1997
Study completion Apr 1997
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.
Conditions
- Carcinoma in Situ
- Bladder Cancer
Interventions
Valrubicin, 800 mgDrug
Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the efficacy of AD 32 (valrubicin) in patients with CIS of the bladder who previously have been treated with BCG for CIS and in whom recurrence or failure had occurred after multiple courses of intravesical treatment.Time frame: 12 weeks
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Stacy Childs, MD
Alabaster, Alabama
William Bohnert, MD
Phoenix, Arizona
Scott Swanson, MD
Scottsdale, Arizona
Bruce Dalkin, MD
Tucson, Arizona
Donald Gleason, MD
Tucson, Arizona
William Friedel, MD
La Mesa, California
Stephen Auerbach, MD
Newport Beach, California
William Moseley, MD
San Diego, California
Standley Brosman, MD
Santa Monica, California
Eugene Dula, MD
Van Nuys, California
B. Thomas Brown, MD
Daytona Beach, Florida
Charles Jackson, MD
Fort Lauderdale, Florida
Marc Soloway, MD
Miami, Florida
Charles Brendler, MD
Chicago, Illinois
Patrick Guinan, MD
Chicago, Illinois
Jeffrey Ignatoff, MD
Evanston, Illinois
David Wood, MD
Lexington, Kentucky
John Tuttle, MD
Lexington, Kentucky
Dennis Venable, MD
Shreveport, Louisiana
Harold Frazier, MD
Bethasda, Maryland
Myron Murdock, MD
Greenbelt, Maryland
John Libertino
Burlington, Massachusetts
W. Lamar Weems, MD
Jackson, Mississippi
Hugh Fisher, MD
Albany, New York
Michael Blute, MD
Rochester, New York
Michael Wolff, MD
Burlington, North Carolina
Cary Robertson, MD
Durham, North Carolina
Eric Klein, MD
Cleveland, Ohio
Bruce Lowe, MD
Portland, Oregon
Jeffrey Cohen, MD
Pittsburgh, Pennsylvania
Jacques Susset, MD
Providence, Rhode Island
L. Dean Knoll, MD
Nashville, Tennessee
Steohen Hardeman, MD
Austin, Texas
Ian Thompson, MD
Fort San Houston, Texas
Seth Lemer, MD
Houston, Texas
Aaron Katz, MD
Richmond, Virginia
Gary Katz, MD
Richmond, Virginia
Williams Ellis, MD
Seattle, Washington
Richard Boxer, MD
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.